Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 13045

Sort by

Sort Order Select

Journal Articles

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W. Roberts, Andrew H. Wei, David C. S. Huang

Blood (2021) 138 (13): 1120–1136.

https://doi.org/10.1182/blood.2020006785

Published: 2021

Journal Articles

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Blood (2021) 138 (9): 811–814.

https://doi.org/10.1182/blood.2021012443

Published: 2021

Includes: Supplemental data

Journal Articles

KRd: the new KiD in the French myeloma induction class

Jeremy Er, Simon J. Harrison

Blood (2021) 138 (2): 105–106.

https://doi.org/10.1182/blood.2021011751

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Plasma cell neoplasm: a unique morphology

Sharon Koorse Germans, Olga Weinberg

Blood (2021) 138 (1): 104.

https://doi.org/10.1182/blood.2021012034

Published: 2021

Journal Articles

Up-front ixazomib in older patients with myeloma

Jean-Luc Harousseau, Mohamad Mohty

Blood (2021) 137 (26): 3584–3586.

https://doi.org/10.1182/blood.2021011262

Published: 2021

Journal Articles

Sensitivity to venetoclax: the B-side of myeloma?

Cyrille Touzeau, Philippe Moreau

Blood (2021) 137 (26): 3582–3583.

https://doi.org/10.1182/blood.2021011146

Published: 2021

Journal Articles

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Ryosuke Shirasaki, David L. Jaye, Jonathan J. Keats, Benjamin Oberlton, Nisha S. Joseph, Craig C. Hofmeister, Leonard T. Heffner, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Constantine S. Mitsiades, Jonathan L. Kaufman, Lawrence H. Boise

Blood (2021) 137 (26): 3604–3615.

https://doi.org/10.1182/blood.2020007899

Published: 2021

Includes: Supplemental data

Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2021) 137 (26): 3616–3628.

https://doi.org/10.1182/blood.2020008787

Published: 2021

Includes: Supplemental data

Journal Articles

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos, Ioannis P. Trougakos, Maria Gavriatopoulou, Ioannis Papassotiriou, Aimilia D. Sklirou, Ioannis Ntanasis-Stathopoulos, Eleni-Dimitra Papanagnou, Despina Fotiou, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2021) 137 (26): 3674–3676.

https://doi.org/10.1182/blood.2021011904

Published: 2021

Journal Articles

Addition by subtraction

Sonja Zweegman, Tanya M. Wildes

Blood (2021) 137 (22): 3005–3006.

https://doi.org/10.1182/blood.2021011144

Published: 2021

Journal Articles

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Charles J. Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood (2021) 137 (21): 2987–2989.

https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

BCMA CARs in multiple myeloma: room for more?

Lydia Sarah Hui Lee, Kwee L. Yong

Blood (2021) 137 (21): 2859–2860.

https://doi.org/10.1182/blood.2021010833

Published: 2021

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Journal Articles

Seed and soil revisited in multiple myeloma

Kate Vandyke

Blood (2021) 137 (17): 2282–2283.

https://doi.org/10.1182/blood.2020009555

Published: 2021

Journal Articles

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Yu Jia Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis-Pistofidis, Robert A. Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu-Tzu Tai, Francois Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial

Blood (2021) 137 (17): 2360–2372.

https://doi.org/10.1182/blood.2020005885

Published: 2021

Includes: Supplemental data

Journal Articles

Familial patterns of hematologic precursors

Ola Landgren, Francesco Maura

Blood (2021) 137 (15): 1992–1993.

https://doi.org/10.1182/blood.2020010035

Published: 2021

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

Zemin Ren, Marcel Spaargaren, Steven T. Pals

Blood (2021) 137 (13): 1713–1718.

https://doi.org/10.1182/blood.2020008188

Published: 2021

Journal Articles

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Blood (2021) 137 (11): 1527–1537.

https://doi.org/10.1182/blood.2020006923

Published: 2021

Includes: Supplemental data

NARROW

BCL2 and MCL1 inhibitors for hematologic malignancies

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

KRd: the new KiD in the French myeloma induction class

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Plasma cell neoplasm: a unique morphology

Up-front ixazomib in older patients with myeloma

Sensitivity to venetoclax: the B-side of myeloma?

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Addition by subtraction

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

BCMA CARs in multiple myeloma: room for more?

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Seed and soil revisited in multiple myeloma

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Familial patterns of hematologic precursors

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only